EE548 Cost-Effectiveness Analysis of Epcoritamab for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy in Greece
Abstract
Authors
C Tzanetakos G Papageorgiou A Wang M Psarra G Gourzoulidis